巨噬细胞游走抑制因子在肿瘤中的作用研究进展  

Macrophage Migration Inhibitory Factor in the Progression of Cancer

作　　者：李瑶[1] 高颖生 吕晓丹[1] 林森森[1] 袁胜涛[1] LI Yao GAO Ying-sheng LV Xiao-dan LIN Sen-sen YUAN Sheng-tao(National Nanjing Center For Drug Screening, China Pharmaceutical University Nanjing, Jiangsu, 210009, China)

机构地区：[1]中国药科大学药物科学研究院江苏省新药筛选重点实验室,江苏南京210009

出　　处：《现代生物医学进展》2017年第20期3992-3995,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81573456;81302794);江苏省自然科学基金项目(BK20161598);国家高技术研究发展计划(863计划)(2014AA022208)

摘　　要：巨噬细胞游走抑制因子是一种具有多种生物学效应的糖蛋白,可以调节不同的下游信号如ERK/AKT、NF-κB等通路参与肿瘤细胞增殖、侵袭、转移、血管形成和自噬等生物学过程。临床相关研究表明巨噬细胞游走抑制因子与肿瘤发生发展关系密切,且在乳腺癌、肺癌、前列腺癌、甲状腺癌、结肠癌等多种肿瘤中高表达,因此以巨噬细胞游走抑制因子为靶点的相关肿瘤治疗逐渐受到重视。有关巨噬细胞游走抑制因子拓扑异构酶活性抑制剂及巨噬细胞游走抑制因子中和抗体在肿瘤治疗中的研究越来越多。本文对巨噬细胞游走抑制因子在肿瘤发生发展中的作用以及针对巨噬细胞游走抑制因子进行的肿瘤治疗研究作一综述。Macrophage migration inhibitory factor （MIF） is a glycoprotein with many biological effects,it participates in lots of biological processes such as tumor proliferation,invasion,metastasis,angiogenesis and autophagy by regulation of different downstream signal pathways like ERK/AKT and NF-κB.Experimental and clinical researches show that MIF is closely related with cancer progression and is high expressed in various types of tumors such as breast cancer,lung cancer,prostate cancer,thyroid cancer and clonal cancer.MIF topoisomerase inhibitor and anti-MIF antibody therapy are now under investigation.Here,we review the effect of MIF in tumorigenesis,and discuss research progress of MIF in cancer treatment.

关 键 词：巨噬细胞游走抑制因子 肿瘤治疗 靶点 

分 类 号：R730.231[医药卫生—肿瘤]